Infliximab maintenance was compared to two other TNF-alpha antagonists (etanercept and adalimumab) administered subcutaneously for RA or spondyloarthritis in a 2016 French study [9]; those authors found that RA patients had a higher retention rate for infliximab (36.88 months) than adalimumab (17.35 months) or etanercept (19.87 months). This evidence concerns the gene TNF and rheumatoid arthritis.